Company* |
Product |
Description |
Indication |
Status |
AUTOIMMUNE | ||||
Alba |
AT-1001 |
Oral zonulin receptor antagonist |
Celiac disease |
Company said it successfully completed a Phase I trial (10/26) |
Biogen Idec |
Tysabri |
Natalizumab; humanized monoclonal antibody that inhibits adhesion molecules on immune cells |
Crohn's disease and rheumatoid arthritis |
Safety evaluation from trials in CD and RA resulted in no new confirmed cases of progressive multifocal leukoencephalopathy (10/17) |
Centocor Inc. |
Remicade (FDA-approved) |
Infliximab; monoclonal antibody that targets tumor necrosis factor-alpha |
Crohn's disease |
Nearly 90% of pediatric patients who previously responded inadequately achieved clinical response at week 10(10/25) |
Centocor Inc. |
Remicade |
Infliximab; monoclonal antibody that targets tumor necrosis factor-alpha |
Ulcerative colitis |
Phase III trial demonstrated mucosal healing and remission, as well as other benefits (10/19) |
Human Genome |
LymphoStat-B |
Belimumab; human monoclonal antibody that inhibits activity of B- lymphocyte stimulator |
Lupus |
Phase II trial in 449 patients showed significance in seropositive subgroup but did not meet overall primary efficacy endpoints (10/5) |
Merrimack |
MM-093 |
Recombinant version of human alpha-fetoprotein; an immunomodulator |
Plaque soriasis |
Began pilot Phase IIa trial to test safety and efficacy in 40 patients with moderate to severe disease (10/13) |
Pharma- |
Tovaxin |
Trivalent formulation of attenuated myelin-peptide reactive T cells |
Multiple sclerosis |
Phase I/II trial demonstrated safety, tolerability and depletion of myelin- peptide reactive T cells (10/3); is starting a Phase IIb trial to evaluate efficacy, safety and tolerability in 150 patients (10/31) |
Targeted |
tgAAC94 |
Product using an adeno-associated viral vector to deliver a soluble TNF-alpha receptor protein |
Inflammatory arthritis |
Began Phase I trial in up to 40 patients already receiving anti-TNF-alpha therapies (10/11); additional data from initial Phase I trial showed improvements in swelling and tenderness (10/31) |
The Immune |
NeuroVax |
T-cell receptor peptide vaccine |
Multiple sclerosis |
Phase I/II trial showed restoration to normal levels of FOXP3 and regulatory T cells, as well as increased IL-10 secretion (10/3) |
Vertex |
VX-765 |
Interleukin-1 beta converting enzyme inhibitor |
Psoriasis |
The company said it was minimizing investment in the drug to focus on more promising opportunities; it is in Phase II (10/6) |
CANCER | ||||
AmpliMed |
Amplimexon |
Imexon injection; a cyanoaziridine compound believed to disrupt mitochondria |
Refractory cancers |
Began Phase I trial that will evaluate drug with docetaxel in 30 patients (10/19) |
Antigenics |
Aroplatin |
Third-generation, liposome- ncapsulated platinum compound |
Advanced cancers |
Began Phase I trial to evaluate safety, dosing and pharmacokinetics in up to 28 patients (10/25) |
Antigenics |
Oncophage |
Personalized cancer vaccine based on heat-shock protein technology |
Metastatic melanoma |
Phase III trial in Stage IV M1a patients showed better than 50% improvement in median survival vs. standard treatments (10/10) |
Biomira Inc. |
BLP25 |
Liposomal vaccine encapsulating a sequence of the MUC1 cancer mucin |
Statge IIIB non-small-cell lung cancer |
Phase IIb trial showed median surival of 30.6 months vs. 13.3 months for the unvaccinated group (10/27) |
CancerVax |
Canvaxin |
Therapeutic whole-cell vaccine that expresses more than 20 antigens |
Stage III melanoma |
Phase III trial was discontinued after monitors determined a survival benefit was unlikely to be seen (10/3) |
Chiron Corp. |
CHIR-12.12 |
Fully human, antagonist antibody that targets the CD40 antigen |
Multiple myeloma |
Began Phase I trial to evaluate safety, tolerability and pharmaco-kinetics in up to 40 patients (10/13) |
Cytogen |
Quadramet (FDA-approved) |
Samarium-153 bound to a small-molecule, bone- seeking phosphonate |
Advanced osteosarcoma |
Eight of 14 patients in trial with gemcitabine had objective radiographic responses(10/7) |
Cytogen |
Quadramet (FDA-approved) |
Samarium-153 bound to a small-molecule, bone- seeking phosphonate |
Hormone- refractory prostate cancer |
Phase II TAXSAM1 trial with docetaxel showed PSA declines of more than 50% in 34% of the 29 patients (10/3) |
Dendreon |
Provenge |
Immunotherapy that uses a recombinant form of the prostatic acid phosphatase antigen |
Metastatic prostate cancer |
Final data from Phase III D9902A trial showed a 19-month median survival vs. 15.7 months for the placebo group (10/31) |
Expression |
EGEN-001 |
Interleukin-12 gene expression plasmid and a biocompatible delivery polymer |
Recurrent epithelial ovarian cancer |
Began Phase I trial in 18 patients that primarily will evalaute safety (10/17) |
Genentech Inc. |
Herceptin |
Trastuzumab; monoclonal antibody against HER2/neu protein |
Early stage breast cancer |
Pivotal Phase II trials showed addition of drug to chemotherapy significantly reduced the risk of recurrence vs. chemotherapy alone (10/19) |
Genentech |
Tarceva |
Erlotinib HCl; small- molecule HER1/EGFR inhibitor |
Metastatic renal cell carcinoma |
Phase II trial with Avastin showed progression-free survival and response rates similar to those achieved with Avastin alone (10/18) |
Halozyme |
Chemophase |
Recombinant agent designed to enhance the delivery of chemotherapy |
Superficial bladder cancer |
Began a Phase I trial with mitomycin to evaluate safety, tolerability and pharmacokinetics in at least five patients(10/27) |
Idera |
HYB2055 |
Toll-like receptor 9 agonist (also known as IMO-2055 or IMOxine) |
Solid tumors |
Began Phase I/II trial with gemcitabine and carboplatin to evaluate safety and efficacy, initially in 12 to 18 refractory patients (10/26) |
Innovive |
INNO-105 |
Naturally occurring peptide that interacts with the OGFr receptor |
Advanced solid tumors |
Got OK to start Phase I trial that will evaluate safety and antitumor effects (10/4) |
Inovio |
SECTA |
Electroporation device used with a chemotherapeutic agent |
Breast cancer |
Began Phase I trial to test the agent for recurrent cancer after a mastectomy or partial mastectomy in up to 24 patients (10/20) |
IRX |
IRX-2 |
Agent designed to stimulate cellular immune responses |
Head and neck cancer |
Began Phase II trial that will evaluate responses in 25 patients with late-stage disease (10/17) |
Kosan |
KOS-862 |
Epothilone D, a polyketide |
Hormone- refractory prostate cancer |
Phase II trial failed to meet end- point on number of patients with a response to therapy (10/18) |
Lorus |
Virulizin |
Immunotherapy agent designed to stimulate the immune system |
Pancreatic cancer |
Phase III trial with gemcitabine in first-line treatment showed promising trends vs. placebo but did not reach statistical significance (10/18) |
Marshall |
Phenoxodiol |
Agent designed to induce apoptosis by removing intracellular proteins XIAP and c-FLIP |
Ovarian cancer and cervical cancer |
Interim data from trial in 43 refractory patients showed improved survival with paclitaxel or cisplatin vs. either agent alone; trial in cervical cancer also showed benefit (10/24) |
Millennium |
MLN518 |
Small molecule designed to inhibit type III receptor tyrosine kinases |
Acute myelogenous leukemia |
Began Phase I/II trial with standard induction therapy to evaluate safety, tolerability and initial response rates in up to 24 patients, and MLN518 alone as a remission maintenance therapy (10/17) |
NeoPharm |
IL13-PE38QQR |
Cintredekin besudotox; agent designed to deliver bacterial cytotoxic PE38 |
Malignant glioma |
Phase I trial in 12 patients provided preliminary support to the feasibility of use in multimodality therapy (10/10) |
Oxford |
TroVax |
Vaccine that delivers an antigen (5T4) using a poxvirus vector |
Renal cell carcinoma |
Preliminary data from Phase II trial showed safety and tolerability, and an immune response against the antigen (10/6) |
OxiGene Inc. |
Combrestatin |
Vascular-targeting agent designed to block the flow of blood to a tumor |
Non-small-cell lung cancer |
Updated Phase Ib/II trial data with radiotherapy showed a statistic- ally significant 40% percent reduction in tumor blood volume (10/5) |
Peregrine |
Tarvacin Anti-Cancer |
Chimeric monoclonal antibody that binds to the phospholipid phosphatidylserine |
Advanced solid tumors |
Began Phase I trial that will assess safety, tolerability and pharmacokinetics in up to 28 patients (10/21) |
Point |
Talabostat |
Small molecule designed to stimulate proliferation of hematopoietic progenitor cells |
Metastatic non- small-cell lung cancer |
Began Phase III trial to evaluate drug with docetaxel vs. docetaxel with placebo in 400 patients (10/13) |
Procyon |
PCK3145 |
Synthetic peptide analogue of prostate secretory protein |
Advanced prostate cancer |
Results to date in dose-finding trial indicate agent is well tolerated and has an impact on MMP-9 plasma levels (10/25) |
Pro- |
Davanat |
Carbohydrate compound designed for targeted delivery |
Cancers |
Phase I trial showed 5-FU remained in the bloodstream significantly longer when given with Davant; increased activity also was seen (10/6) |
Reata |
RTA 401 |
Synthetic triterpenoid; targeted anticancer agent |
Relapsed leukemias |
Began trial to evaluate safety, dosing, side effects and efficacy in 401 patients (10/12) |
RxKinetix Inc.* |
RK-0202 |
The antioxidant N- acetylcysteine in a polymer matrix |
Oral mucositis in cancer patients |
Monitors recommended stopping enrollment in Phase II trial in order to expedite development, after reviewing data on 114 of planned 130 patients (10/18) |
Telik Inc. |
Telintra |
Glutathione analogue inhibitor of GST P1-1 |
Myelodysplastic syndromes |
Got OK to begin initial trial of an oral formulation of the drug in patients (10/6) |
Xanthus Life |
Xanafide |
Salt formulation of the cancer compound amonafide |
Secondary acute myeloid leukemia |
Began Phase II trial with ara-C to evaluate remissions and survival in up to 60 patients(10/20) |
YM |
Tesmilifene (DPEE) |
Small molecule designed to augment the activity of chemotherapy agents |
Hormone-refractory prostate cancer |
Phase II trial with mixantrone/ prednisone showed PSA decreases, reduced symptoms and a two-year survival rate of 21% (10/13) |
CARDIOVASCULAR | ||||
ActivBiotics |
Rifalazil |
Anti-chlamydial agent |
Peripheral arterial disease |
Said it is starting a 160-patient Phase III trial named PROVI- DENCE-1 that will assess symptom improvement (10/6) |
Cardiome |
RSD1235 |
Formulation of drug designed to selectively block ion channels in the heart |
Atrial arrhythmia |
Began open-label ACT 4 trial to evaluate the safety of intravenous RSD1235 in 120 patients (10/19) |
CardioVascular |
Cardio Vascu-Grow |
Stimulator of angiogenesis |
Heart conditions |
Monitors reviewing safety data in Phase I trial OK'd move into the final dosing group (10/4) |
Centocor Inc. |
ReoPro |
Abciximab; an anticlotting agent |
Acute ischemic stroke |
Enrollment in Phase II AbESTT trial was temporarily suspended after monitors observed safety concerns (10/4); enrollment was permanently discontinued (10/28) |
CoTherix Inc. |
Ventavis |
Inhaled formulation of iloprost, a prostacyclin analogue |
Pulmonary arterial hypertension |
Phase II trial showed the addition of drug to Tracleer produced similar safety trends and improvements in secondary endpoints (10/31) |
Forbes |
FM-VP4 |
Amphipathic analogue of phytostanols; a cholesterol absorption inhibitor |
Cholesterol control |
The company is starting a Phase II trial (10/3) |
Icagen Inc. |
ICA-17043 |
Ion channel blocker |
Sickle cell anemia |
Open-label extension of Phase II trial provided further positive safety and tolerability data (10/19) |
Lumen |
LT-1951 |
Polymer of L-arginine, the substrate for production of nitric oxide |
Prevention of graft failure |
Phase I portion of Phase I/II trial demonstrated tolerability and safety in 20 patients (10/3) |
Speedel |
SPP635 |
Renin inhibitor |
Hypertension |
Began Phase I trial to evaluate safety, tolerability, pharmacokinetics and renin-angiotensin inhibition in healthy volunteers (10/13) |
Surface |
SLx-2101 |
Selective, oral PDE-5 inhibitor |
Cardiovascular diseases |
Phase I trial indicated the product was safe, well tolerated and pharmacodynamicaly active (10/11) |
Synthetic Blood |
Oxycyte |
Perfluorocarbon-based |
Blood substitute |
Plans to begin Phase II trials in patients with traumatic brain injury and with sickle cell anemia; is suspending enrollment in Phase II trial in patients with hip-revision surgery (10/4) |
The Medicines |
Clevelox |
Intravenous L-calcium channel blocker |
For use in cardiac surgery |
Resumed Phase III trial after data review showed no safety concerns; studies were stopped in March due to possible increases in atrial fibrillation (10/19) |
ZymoGenetics |
rhThrombin |
Recombinant human thrombin |
Controlling blood loss during surgery |
Began pivotal Phase III trial to test efficacy vs. bovine-derived thrombin in at least 400 patients undergoing surgery (10/27) |
CENTRAL NERVOUS SYSTEM | ||||
Aeolus |
AEOL 10150 |
Small-molecule catalytic antioxidant |
Amyotrophic lateral sclerosis |
Began follow-on Phase I trial that will evaluate the agent in 18 patients (10/19) |
AlgoRx |
ALGRX 3268 |
Anesthetic administered into the skin by Powderject system |
Morton's neuroma |
Phase II trial in 30 patients showed statistically significant decreases in foot pain vs. placebo (10/18) |
AlgoRx |
ALGRX 3268 |
Anesthetic administered into the skin by Powderject system |
Pain |
Phase III trial in 574 pediatric patients demonstrated statistically significant less pain for drug group vs. placebo (10/5) |
Cephalon |
Sparlon |
New formulation and dosage of modafinil, the active ingredient in the approved product Provigil |
Attention deficit/ hyperactivity disorder |
Data from three pivotal Phase III trials in a total of 600 children aged 6 to 17 showed significant improvements vs. placebo (10/21) |
Durect Corp. |
Memryte |
Durin implant technology with leuprolide acetate |
Alzheimer's disease |
Began pivotal Phase III trial to test product as an adjunctive therapy with acetyl cholinesterase inhibitors in about 1,100 patients with mild to moderate disease (10/14) |
Endo |
Lidoderm |
Lidocaine patch 5% |
Pain from carpal tunnel syndrome |
Open-label pilot study showed drug compared favorably with those treated with a cortico-steroid injection (10/27) |
Endo |
Oxymorphone ER |
Extended-release formulation of oxymorphone |
Pain |
Second Phase III trial in 142 patients with chronic low-back pain showed a statistically significant improvement vs. placebo (10/3) |
Javelin |
Rylomine |
Intranasal morphine |
Pain |
Phase II trial in 187 post-bunionectomy patients showed statistically significant pain relief vs. placebo (10/12) |
Neurochem |
Alzhemed |
Small molecule designed to interfere with association between glycosamino- glycans and A-beta protein |
Alzheimer's disease |
Monitors recommended continuation of Phase III trial following a safety review on 1,042 patients (10/5) |
Repligen Corp. |
RG1068 |
Synthetic human secretin |
Schizophrenia |
Began follow-on trial in 30 patients to assess the impact on a marker for a cognitive deficit characteristic of schizophrenia patients (10/6) |
Sepracor |
SEP-225289 |
Triple reuptake inhibitor |
Major depressive disorder |
Began Phase I trial to evaluate safety, tolerability and pharmacokinetics (10/19) |
StemCells Inc. |
HuCNS-SC |
Human neural stem cells |
Batten disease |
Got OK from FDA to begin Phase I trial to evaluate safety and preliminary efficacy in children (10/20) |
DIABETES | ||||
Advanced Viral |
AVR118 |
Peptide-nucleic acid complex with immuno-modulatory properties |
Type II diabetes |
Began Phase I trial to evaluate safety and effect on blood glucose in 30 patients (10/3) |
INFECTION | ||||
Antigenics |
AG-707 |
Recombinant heat-shock protein 70 polyvalent peptide complex |
Genital herpes |
Began Phase I trial to evaluate safety and immune responses in 84 patients with HSV-2 (10/18) |
Biolex |
BLX-883 |
Form of alfa interferon manufactured using firm's LEX System |
Hepatitis C |
Phase I trial in 24 healthy volunteers supported continued development (10/26) |
Cerexa Inc.* |
PPI-0903 |
Broad-spectrum cephalosporin antibiotic |
Complicated skin and skin structure infections |
Began Phase II trial to evaluate efficacy and safety vs. standard therapy in 100 patients (10/19) |
Chiron Corp. |
-- |
Cell culture-derived influenza vaccine |
Influenza |
Began a Phase I/II trial of the vaccine (10/25) |
Chiron Corp. |
TIP |
Tobramycin inhalation powder |
Lung infections caused by P. aeruginosa |
Began Phase III ASPIRE I trial to test efficacy and safety for lung infections in patients with cystic fibrosis (10/5) |
Elusys |
Anthim |
Monoclonal antibody that targets the protective antigen component of anthrax |
Anthrax infection |
Began Phase I trial to test safety, tolerability and pharmacokinetics of a single dose in healthy volunteers (10/3) |
Koronis |
KP-1461 |
Agent that targets HIV mutation to force the production of a nonfunctional virus |
HIV |
Began Phase Ib trial to evaluate safety, toxicity, pharmacokinetics and initial clinical activity in 40 patients who failed HAART regimens (10/12) |
Medarex Inc. |
CDA-1 |
Fully human antibody believed to target and neutralize the effects of Toxin A |
Clostridium difficile- associated diarrhea |
Began Phase II trial to assess safety, tolerability and efficacy with standard care in up to 150 patients (10/11) |
Nabi Bio- |
Altastaph |
Staphylococcus aureus immune globulin |
S. aureus infections |
Phase I/II trial showed a shorter duration of bacteremia and fever vs. placebo, and shorter hospital stays (10/7) |
Nabi Bio- |
StaphVAX |
Staphylococcus aureus polysaccharide conjugate vaccine |
To prevent S. aureus infections |
Successfully completed studies of three commercial-scale lots of the vaccine in 354 healthy adults (10/12) |
Oscient |
Factive |
Gemifloxacin mesylate; a fluoroquinolone antibiotic |
Acute bacterial sinusitis |
Meta-analysis of pooled Phase III studies showed drug was more effective than two others in ABS patients with allergic rhinitis (10/7) |
Tanox Inc. |
TNX-355 |
Humanized anti-CD4 monoclonal antibody; designed to inhibit viral entry |
HIV |
Phase II trial with optimized background therapy produced a statistically significant reduction in viral load vs. therapy and placebo (10/26) |
Vertex |
Merimepodib (VX-497) |
Small-molecule inhibitor of the enzyme inosine mono- phosphate dehydrogenase |
Hepatitis C |
The company said it was minimizing investment in the drug to focus on more promising opportunities; it is in Phase II (10/6) |
Vertex |
VX-950 |
Oral HCV protease inhibitor |
Hepatitis C |
14-day study showed serum ALT declines in patients with genotype 1 HCV infection (10/3) |
Vical Inc. |
-- |
Plasmid DNA vaccine that incorporates parts of four HIV genes |
HIV |
Began NIH-sponsored Phase II trial in which responses will be boosted afterward with a single dose of an adenoviral vector vaccine (10/11) |
MISCELLANEOUS | ||||
Acuity |
Cand5 |
Small interfering RNA therapeutic designed to shut down VEGF |
Age-related macular degeneration |
Began Phase II trial in 30 patients and reported that Phase I trial demonstrated safety and tolerability (10/14) |
Arena |
APD356 |
Stimulator of the 5-HT2C serotonin receptor |
Obesity |
Phase IIa trial demonstrated a statistically significant weight loss in patients taking the 15-mg dose (10/18) |
Cobalis Corp. |
PreHistin |
Agent designed to modulate levels of IgE, reducing the overproduction of histamines |
Allergy |
Phase III trial in 714 patients demonstrated statistically significant fewer allergy symptoms vs. placebo (10/27) |
DUSA |
Levulan |
Aminolevulinic acid HCl; photodynamic therapy |
Photodamaged skin |
Trial with intense pulsed light in 20 patients showed significant improvement vs. IPL alone (10/20) |
Eyetech |
Macugen |
Pegaptanib sodium injection; pegylated anti-VEGF aptamer |
Diabetic macular edema and diabetic retinopathy |
Began Phase III trial to evaluate safety and efficacy in 900 patients treated over three years; the move followed a prospective analysis of the Phase II trial (10/17) |
Eyetech |
Macugen |
Pegaptanib sodium injection; pegylated anti-VEGF aptamer |
Wet age-related macular degeneration |
Retrospective analysis showed drug may work better in patients with early stage neovascular AMD vs. overall study population (10/5) |
FoldRx |
Fx-1006A |
Small-molecule compound designed to inhibit the formation of amyloid deposits |
Certain genetic disorders |
Began Phase I trial to evaluate safety, tolerability and pharmacologic properties in 55 healthy volunteers (10/12) |
Genaera |
Evizon (squalamine) |
Anti-angiogenesis agent; vascular endothelial growth factor inhibitor |
Wet age-related macular degeneration |
Phase II trial with Visudyne in 45 subjects met its primary goal of demonstrating safety; a slight increase in mean visual acuity was seen (10/11) |
Hollis-Eden |
Neumune |
Immune-regulating hormone |
Acute radiation syndrome |
Preliminary Phase I data demonstrated safety and tolerability and an increase in neutrophils and platelets; trial was in healthy volunteers (10/18) |
ICOS Corp. |
Tadalafil |
Cialis; oral PDE5 inhibitor |
Benign prostatic hyperplasia |
Phase II trial demonstrated statistically significant improvement in the severity of symptoms (10/12) |
Inspire |
Denufosol |
P2Y2 receptor agonist |
Cystic fibrosis |
Completed Phase II safety trial that will help with design of Phase III program (10/13) |
ISTA |
Vitrase |
Ovine hyaluronidase formulation |
Vitreous hemorrhage |
Pooled, subset analysis of Phase III trials showed a three-line improvement on an eye chart vs. a saline control (10/20) |
Kemia Inc.* |
KC706 |
Agent designed to inhibit the activity of p38 MAP kinase |
Inflammatory diseases |
Began a Phase I trial to test safety in healthy volunteers (10/6) |
Microbia Inc.* |
MD-1100 |
Peptide designed to act on guanylate cyclase-C, a receptor found on the surface of intestinal cells |
Irritable bowel syndrome |
Phase I trial in healthy volunteers showed the drug was well tolerated (10/31) |
Miravant |
Photrex (SnET2) |
Photodynamic therapy that uses a light-activated drug to destroy abnormal blood vessels |
Wet age-related macular degeneration |
Began Phase III trial in 650 patients to fulfill requirements set out in September 2004 approvable letter from the FDA (10/10) |
Nymox |
NX-1207 |
Investigational agent for BPH |
Benign prostatic hyperplasia |
Second interim analysis of Phase II trial revealed no serious drug side effects (10/12) |
Osiris |
Prochymal |
Intravenous formulation of mesenchymal stem cells |
Graft-vs.-host disease |
Is starting a Phase II trial to test safety and efficacy in patients with treatment-refractory disease (10/12) |
Savient |
Puricase |
Polyethylene glycol conjugate of uricase |
Gout |
Phase II trial demonstrated sustained lowering of plasma urate levels in the majority of patients (10/3) |
Sirna |
Sirna-027 |
Chemically modified short interfering RNA targeting vascular endothelial growth factor receptor-1 |
Age-related macular degeneration |
Data from 22 patients in Phase I trial showed all patients had acuity stabilization and 23% had improved visual acuity (10/19) |
Symbollon |
IoGen |
Iodine-based oral drug |
Proliferative benign breast disease |
Is starting a trial to evaluate the clinical effects of agent in about 20 women (10/20) |
Urigen Inc.* |
U101 |
Intravesical formulation of FDA-approved components |
Interstitial cystitis |
Is starting a Phase IIb trial to evaluate safety and efficacy (10/3) |
XenoPort |
XP19986 |
Transported prodrug of R-baclofen |
Gastro-esophageal reflux disease |
Began Phase IIa trial to evaluate safety, tolerability and efficacy (10/26) |
Notes: | ||||
* Privately held. | ||||
BLA = Biologics license application; FDA = Food and Drug Administration; IND = Investigational new drug application; NDA = New drug application; SPA = Special protocol assessment. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange. | ||||
